about
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamineFirst-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells.Expression of Id-1 and VEGF in non-small cell lung cancer.Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion.Sorafenib in non-small cell lung cancer.Monoclonal antibodies in lung cancer.Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration.Role of polymer-drug conjugates in organ-specific delivery systems.Bronchial Artery Angiogenesis Drives Lung Tumor Growth.Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium.Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in experimental non-small cell lung cancer.(-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.Potential anti-cancer effect of curcumin in human lung squamous cell carcinoma.Isolation and characterization of three new anti-proliferative Sesquiterpenes from Polygonum barbatum and their mechanism via apoptotic pathway.
P2860
Q28488021-F23AA578-68A9-42A5-B418-026794733819Q33401434-9E938616-EDF4-4EB1-B859-4BC5CA93EBF7Q35545472-BECF431E-E787-42E7-B4CE-F871C44D071BQ36904634-E84C4A80-BCDD-4539-93EF-C0965A77B823Q37228842-9BE9239A-8B5D-4247-8780-11057C0A59B3Q37468177-0CFF9D50-9FA0-4EF2-AE76-66D5AE29371FQ38020917-E830CDB6-E3F7-47CE-A8E0-F47881F345D3Q38067454-03A03DDE-1780-4CA8-A88D-A13F377D3C71Q38292799-2A9872B9-D0E8-4CEE-AEF6-96E22ED79560Q38365556-91A8D846-68A2-4336-8463-01202EEED134Q38749575-91ADD7B0-2C74-4F0B-BF74-A2A469631A0CQ38832390-3FC4A6EA-F1D8-496C-8C48-5940667604C5Q38997663-50145D8E-C65B-48AD-BAD5-4C1D38E5D22FQ39215796-0BC4E95A-9C38-4A3B-811C-FE747DF12E8FQ42282831-8284E99F-AB11-45A1-BCB1-3766F0F7503BQ42643167-9A002A28-3F6B-40D4-B14D-D8E38707EBE2
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting VEGF in lung cancer.
@en
Targeting VEGF in lung cancer.
@nl
type
label
Targeting VEGF in lung cancer.
@en
Targeting VEGF in lung cancer.
@nl
prefLabel
Targeting VEGF in lung cancer.
@en
Targeting VEGF in lung cancer.
@nl
P2860
P1476
Targeting VEGF in lung cancer.
@en
P2093
Heather Wakelee
Millie Das
P2860
P304
P356
10.1517/14728222.2012.669752
P407
P577
2012-03-23T00:00:00Z